Investor News

Home>News>Investor News

Cartherics-led Consortium Receives $5.4M Federal Funding for Cellular Immunotherapy Research into Ovarian and Gastric Cancers

MELBOURNE, Australia, 27 September 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, together within partner institutions, has received $5.4M Medical Research Futures Fund (MRFF) grant to develop a new approach to enhance cancer therapy by engaging the patients’ own immune system to complement CAR cell therapy.

The company, in […]

2022-09-30T16:02:08+10:00September 30th, 2022|

Cartherics Board Member hits the Airwaves

On Thursday, 2 September, in an interview with Jack Hodgins on 2NUR.FM’s ‘Wellbeing’ segment, Professor Bryan Williams (Cartherics Non-Executive Board Member) spoke about COVID-19, viruses and how vaccines control them, and the importance of medical research.

“I would encourage Australians to convince their politicians that they need to increase the research budget in Australia, […]

2021-09-14T12:41:24+10:00September 14th, 2021|

Cartherics, ARMI and CCRM Australia announce new agreement for closer cooperation and collaboration

Cartherics Pty Ltd and the Australian Regenerative Medicine Institute (ARMI), including commercialisation initiative CCRM Australia, announced agreements for closer cooperation and collaboration today.

“Cartherics affiliation with ARMI is an important step in our development and will embed industry and academic excellence in regenerative medicine and translation to clinical medicine in cancer,” said Prof Alan Trounson, Cartherics […]

2021-07-05T09:56:45+10:00July 5th, 2021|

Super-Charging the Immune System to Fight Cancer

Innovative immunotherapies for cancer are a step closer to reality thanks to a commercial licence agreement between Australia’s Cartherics Pty. Ltd. and South Korea-based ToolGen, Inc.

Melbourne, Australia and Seoul, South Korea

28 June 2021

Cartherics Pty Ltd (“Cartherics”) and ToolGen, Inc. (“ToolGen”) announced today that they have entered into a commercial licence agreement.

Under the agreement, Cartherics obtains […]

2021-06-28T10:00:38+10:00June 28th, 2021|

New Cancer Therapy Brings Hope

Battling blood cancer in my 20s, I put my faith in a clinical trial for a promising new CAR-T treatment.

But does it actually work?

By Hayden Smith, 7 June 2021

‘It was mid-March at Fiona Stanley Hospital in Perth, and a squadron of doctors and nurses had gathered by my bed. Some were methodically […]

2021-06-07T13:00:54+10:00June 7th, 2021|

Cancer survivor Heather Hawkins was devastated by news that early detection of ovarian cancer doesn’t save lives …..

But she has “unshakeable hope” that Cartherics’ innovative treatments promise an alternative path

By Heather Hawkins

24 May 2021

Ovarian Cancer: two words that changed my life forever.

Even today – and it’s been 14 years since diagnosis – they still evoke a very raw and deeply emotional response. It was the first time I’d faced the undeniable fact […]

2021-05-24T14:13:27+10:00May 24th, 2021|

Cartherics Therapies More Essential Than Ever

New research delivers devastating findings about ovarian cancer screening

Four Australian women are diagnosed with ovarian cancer a day and three will eventually die from the disease. It’s usually diagnosed late, because few women show symptoms until they have advanced cancer.

As a junior doctor in London in the mid-1980s, Ian Jacobs saw women undergo chemo and […]

2021-05-20T14:20:54+10:00May 20th, 2021|

Cartherics CEO Alan Trounson remembers Dolly and welcomes Elizabeth Ann

Dolly the cloned sheep is a legend. Not so her technical descendant Elizabeth Ann the endangered black-footed ferret.

By Leigh Dayton

4 March 2021

In 1966 Alan Trounson was enjoying a hike in the hills above Edinburgh, Scotland with his colleague Ian Wilmut when Wilmut revealed a secret. His team at the Roslin Institute had cloned a […]

2021-03-04T11:35:02+11:00March 4th, 2021|

CAR-T Funding is Reaching Staggering New Heights

A survey reveals nearly US$100 market capitalisation

23 February 2021

A survey conducted by Washington DC based BioInformant assesses the growth of the CAR-T arm of immunotherapy research and development. The summary is posted below.

At first the trend was subtle, but the tide has swelled as CAR-T therapies like Kymriah, Yescarta, Tecartus, and […]

2021-04-28T12:42:46+10:00February 23rd, 2021|

Cartherics CEO Alan Trounson on “3-person IVF”

Legislation to be introduced to Australian Parliament

By Leigh Dayton

4 February 2021

Not only is Alan Trounson Cartherics CEO and a leader in embryonic stem cell science, he’s also a pioneer in IVF technology. Back in 1980 the then embryologist made headlines for his participation in the birth of Australia’s first IVF baby, Candice Reed.

Thanks to this […]

2021-02-04T03:41:18+11:00February 4th, 2021|
Go to Top